The company is developing gene therapy targeting K-RAS mutations in lung cancer, utilizing orchestrated gene-driven defense mechanisms to enhance patient outcomes. This approach provides treatment options for patients with limited alternatives, aiming to improve clinical results beyond current standards of care.
Funding
$7.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Lung cancer patients with K-RAS mutations often face limited treatment options and poor prognoses due to the difficulty in targeting these mutations effectively. Current standards of care may not provide satisfactory outcomes for these patients.
Solution
This company is developing gene therapies designed to target K-RAS mutations in lung cancer, offering a novel approach for patients with limited alternatives. Their first-in-class drug candidates aim to overcome the challenges associated with treating Pan K-RAS cancers by utilizing orchestrated gene-driven defense mechanisms. The goal is to improve clinical results beyond current standards of care and provide transformational treatment options for patients who have no other options. This approach seeks to enable more effective and targeted therapies for this specific subset of lung cancer patients.
Target Audience
The primary target audience is lung cancer patients with K-RAS mutations who have limited or no effective treatment options available.
Features
- Gene therapy targeting K-RAS mutations
- Orchestrated gene-driven defense mechanisms
- First-in-class drug candidates designed to overcome Pan K-RAS cancer